SCHEMBL21644779

SCHEMBL21644779

CCc1cccc2c(C[C@H](N)C(=O)O)c[nH]c12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.62
KMT2A Q03164 4/20 0.62
LMNA P02545 3/20 0.62
KDM4E B2RXH2 3/20 0.62
MEN1 O00255 3/20 0.62
TSHR P16473 2/20 0.62
BLM P54132 2/20 0.62
PMP22 Q01453 2/20 0.62
MPO P05164 1/20 0.62
HIF1A Q16665 1/20 0.62
TNF P01375 1/20 0.57
ALDH1A1 P00352 3/20 0.51
HTT P42858 1/20 0.51
CYP3A4 P08684 1/20 0.51
HTR1A P08908 1/20 0.51
ADORA3 P0DMS8 1/20 0.51
ALOX15 P16050 1/20 0.51
NFKB1 P19838 1/20 0.51
HTR2A P28223 1/20 0.51
HTR2C P28335 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21644780 1.00 MAPT (0.62) MAPTKMT2ALMNAKDM4EMEN1
SCHEMBL29379020 1.00 MAPT (0.62) MAPTKMT2ALMNAKDM4EMEN1
SCHEMBL31727869 0.89 MAPT (0.55) MAPTKMT2ALMNAKDM4EMEN1
SCHEMBL10023253 0.86 SOS2 (0.68) MAPTKMT2ALMNAKDM4EMEN1
SCHEMBL29405720 0.86 SOS2 (0.68) MAPTKMT2ALMNAKDM4EMEN1
SCHEMBL2033277 0.86 SOS2 (0.68) MAPTKMT2ALMNAKDM4EMEN1
SCHEMBL31369774 0.86 SOS2 (0.68) MAPTKMT2ALMNAKDM4EMEN1
SCHEMBL2033276 0.86 SOS2 (0.68) MAPTKMT2ALMNAKDM4EMEN1
SCHEMBL1460650 0.86 MAPT (0.69) MAPTKMT2ALMNAKDM4EMEN1
SCHEMBL18029110 0.86 MAPT (0.69) MAPTKMT2ALMNAKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018057-B2 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases JANSSEN BIOTECH, INC. (US) 2024-06-25 US disclosed
US-12018057-B2 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases JANSSEN BIOTECH, INC. (US) 2024-06-25 US disclosed
US-12018057-B2 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases JANSSEN BIOTECH, INC. (US) 2024-06-25 US disclosed
CN-118055773-A Lipopeptides inhibitors of interleukin-23 receptor 詹森生物科技公司 2024-05-17 CN disclosed
CN-113929612-B Preparation method of etodolac intermediate 鲁南制药集团股份有限公司 2024-05-14 CN disclosed
CN-117999274-A Peptide inhibitors of interleukin-23 receptor 詹森生物科技公司 2024-05-07 CN disclosed
CN-117980320-A Bicyclic peptide inhibitors of interleukin-23 receptor 詹森生物科技公司 2024-05-03 CN disclosed
CN-113666860-B Preparation method of 7-ethyl tryptol 鲁南制药集团股份有限公司 2024-03-15 CN disclosed
US-11845808-B2 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases JANSSEN BIOTECH, INC. (US) 2023-12-19 US disclosed
US-20220402983-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES JANSSEN BIOTECH, INC. 2022-12-22 US disclosed
CN-115298196-A Peptide inhibitors of the interleukin-23 receptor and their use for the treatment of inflammatory diseases 詹森生物科技公司 2022-11-04 CN disclosed
US-11041000-B2 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases PROTAGONIST THERAPEUTICS, INC. (US) 2021-06-22 US disclosed
US-20210009638-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES PROTAGONIST THERAPEUTICS, INC. 2021-01-14 US disclosed
US-20200040037-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES PROTAGONIST THERAPEUTICS, INC. 2020-02-06 US disclosed
US-20200040037-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES PROTAGONIST THERAPEUTICS, INC. 2020-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11041000-B2 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases IL23R, IL1RN, VIP MAPT 2759/4885KMT2A 4527/4885LMNA 4161/4885
US-20220402983-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES IL23R, IL1RN, VIP MAPT 2759/4885KMT2A 4527/4885LMNA 4161/4885
US-12018057-B2 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases IL23R, IL1RN, VIP MAPT 2759/4885KMT2A 4527/4885LMNA 4161/4885
US-11845808-B2 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases IL23R, IL1RN, VIP MAPT 2759/4885KMT2A 4527/4885LMNA 4161/4885
US-20200040037-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES IL23R, IL1RN, VIP MAPT 2759/4885KMT2A 4527/4885LMNA 4161/4885
US-20210009638-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES IL23R, IL1RN, VIP MAPT 2759/4885KMT2A 4527/4885LMNA 4161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.